Around 8 million people in the United States rely on insulin to manage their diabetes, but steady price increases have made the life-saving medicine increasingly more difficult to afford. As many as one in four insulin users have reported having to skip doses or use less of the drug than prescribed for cost reasons.
Recent measures by Congress cap monthly out-of-pocket costs at $35 for Medicare recipients, and insulin-makers have cut their list prices for certain products, but not all patients stand to benefit.
One biotech startup, rBIO of Houston, is aiming to make insulin more
→ Continue reading at Wired - Science